Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Gluten Technology and Education for Celiac Health

NCT06059716 · View on ClinicalTrials.gov ↗

Study Summary

The investigators propose to plan for a multi-center randomized controlled trial (M-RCT) to test the effectiveness of novel gluten detection technologies as an adjunct to telemedicine to manage celiac disease in newly diagnosed adults. If successful, the proposed intervention will improve mucosal recovery, promote a shift in current practice of celiac disease management toward long-term monitoring, and represent a significant step toward reducing the severe physical and psychological consequences of celiac disease.

Conditions Studied

Interventions

  • BEHAVIORAL Gluten detection technology
  • BEHAVIORAL Continuous telemedicine monitoring

Study Locations (4)

Illinois

  • University of Chicago Medical Center — Chicago

Massachusetts

  • Beth Israel Deaconess Medical Center — Boston

New York

  • Columbia University Irving Medical Center — New York

Tennessee

  • Vanderbilt University Medical Center — Nashville

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-10-08
Est. Completion 2028-08-31
Phase NA

Sponsor

Columbia University

875 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06059716

The ClinicalTrials.gov registry entry for NCT06059716 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 875 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 2 interventions — of which Gluten detection technology is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06059716 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Illinois, Massachusetts, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06059716 about?

NCT06059716 is a clinical study titled "Gluten Technology and Education for Celiac Health". The investigators propose to plan for a multi-center randomized controlled trial (M-RCT) to test the effectiveness of novel gluten detection technologies as an adjunct to telemedicine to manage celiac disease in newly diagnosed adults. If successful, the proposed intervention will improve mucosal re...

What is the current status of trial NCT06059716?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-10-08. Estimated completion is 2028-08-31.

What conditions does trial NCT06059716 study?

This clinical trial studies the following conditions: Celiac Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06059716?

The interventions under investigation include: Gluten detection technology (BEHAVIORAL), Continuous telemedicine monitoring (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06059716?

This trial is sponsored by Columbia University, which has 875 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06059716 being conducted?

This trial has 4 study locations across Illinois, Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial